Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer: A case report

M. Schaffer, A. Hofstetter, B. Ertl-Wagner, R. Batash, J. Pöschl, P. M. Schaffer

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Introduction: Astrocytomas are neoplasms that originate from glial cells. Anaplastic astrocytoma is classified as WHO III, with 27 % of the individuals with grade III astrocytoma living for at least 5 years even after treatment (radiation and chemotherapy). Photofrin II has been demonstrated to serve as a specific and selective radiosensitizing agent in both in vitro and in vivo tumor models. Material and methods: This case report presents a woman suffering from an inoperable astrocytoma WHO III since 2004. The patient was treated with radiation therapy and Photofrin II as a radiosensitiser. The patient underwent irradiation with 40 + 20 Gy boost. The patient was given a single intravenous dose of 1 mg/kg Photofrin II 24 h prior to the initiation of radiation therapy. Results: The patient is still alive without any significant side effect with a follow up of 106 months. MRI shows no evidence of disease. Conclusion: The follow-up results are encouraging regarding the application of Photofrin II as an effective radiosensitizing agent in the treatment of inoperable WHO III astrocytoma.

Original languageEnglish
Pages (from-to)972-976
Number of pages5
JournalStrahlentherapie und Onkologie
Issue number11
StatePublished - 1 Nov 2013
Externally publishedYes


  • Astrocytoma grade III
  • Dihematoporphyrin ether
  • Glioma
  • Irradiation
  • Selective and specific radiosensitizer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology


Dive into the research topics of 'Treatment of astrocytoma grade III with Photofrin II as a radiosensitizer: A case report'. Together they form a unique fingerprint.

Cite this